Humana Inc.

Humana did not provide consolidated revenue or EPS figures in the prepared remarks or Q&A transcript excerpt. Celeste Mellet said the 2Q consolidated operating cost ratio was down 120 basis points year over year, and the company continues to expect a full-year reduction of approximately 150 basis points. She also said 2026 cost trend is assumed in the high single-digit range, or 7% to 8%, inclusive of both medical and pharmacy. For 2027, management expects meaningful margin expansion versus 2026, with actual results dependent on final membership size and mix, and said approximately 600,000 members could be affected by plan exits, with a significant portion expected to be recaptured. Management also said the Gentiva minority interest divestiture is valued at approximately $900 million and expected to close in the fourth quarter, and that $1.5 billion of contingent capital facilities were established through P-Caps.

Jim Rechtin struck a confident but measured tone, saying the company is pleased with year-to-date performance, is tracking to expectations, and is on track to meet its Investor Day commitments. He emphasized the 2027 MA bid strategy as a deliberate step toward reaching a sustainable pretax margin of at least 3% in 2028, while also stressing continued investment in Stars, operational simplification, and member growth. He framed the company’s work as improving outcomes and competitiveness at the same time, rather than chasing short-term gains.

Celeste Mellet focused on execution against financial targets and balance sheet discipline. She said 2026 cost trends are within expectations at 7% to 8%, with slight inpatient favorability and particularly favorable claims experience among members engaged with value-based providers. She added that the 2Q consolidated operating cost ratio improved by 120 basis points year over year, that the company still expects roughly 150 basis points of full-year improvement, and that Humana remains on track to double its individual MA pretax margin this year excluding the Stars headwind. On capital and liquidity, she highlighted $1.5 billion in contingent capital facilities via P-Caps, the approximately $900 million Gentiva divestiture, and a prudent capital deployment approach.

Analysts focused heavily on 2027 MA bid strategy, cost trend assumptions, Stars, and balance sheet actions. Management said it would not quantify specific margin movement from 2026 to 2027, but expects significant progress and noted that higher drug trend and membership mix will affect the outcome. On Stars, Rechtin said the company shared only a representative subset of metrics, is confident in its operational progress, and will go dark during the CMS blackout period until final data is released. On IBNR, Mellet said it remained basically flat sequentially from the prior quarter and was up year over year versus the start of the year, while on the CMS premium stabilization program, Rechtin said the possible end of the demo was already contemplated in bids and does not change the outlook materially.